Phadia AB Chooses Aushon Biosystems Microarray Technology to Accelerate Diagnostic Allergen and Autoimmunity Assay Development

BILLERICA, Mass.--(BUSINESS WIRE)--Aushon BioSystems, Inc., a leading provider of advanced microarray instrumentation and laboratory services for biomarker discovery, development and analysis, announced today that Phadia, the world leader in allergy blood testing diagnostics, will utilize the Aushon 2470 Arrayer technology in its Multiplexing Diagnostics GmbH division. The 2470 will enable Phadia to advance its research efforts focusing on the characterization of new allergens, and the discovery of patterns in molecular diagnosis for allergy and autoimmunity.

MORE ON THIS TOPIC